• Efficacy of 8 Weeks Treatment With Glecaprevir-Pibrentasvir in an Integrated Analysis of Patients With Chronic HCV Infection

Efficacy of 8 Weeks Treatment With Glecaprevir-Pibrentasvir in an Integrated Analysis of Patients With Chronic HCV Infection

Eight weeks treatment with glecaprevir-pibrentasvir was efficacious and well tolerated in treatment-naive patients with all hepatitis C virus (HCV) genotype infections, with or without cirrhosis, researchers report in a pooled analysis of studies in the October issue of Clinical Gastroenterology and Hepatology. In a post-hoc analysis of data from 8

Read more

What IBD Treatments are Associated With Adverse Outcomes in Patients With COVID-19?

Among patients with inflammatory bowels diseases (IBD), older age, increased number of comorbidities, and use of systemic corticosteroids are strong risk factors for adverse outcomes from COVID-19, researchers report in the September issue of Gastroenterology. Maintenance of remission with steroid-sparing treatments is therefore important in management of patients with IBD

Read more

What Drinks Increase Risk of Reflux Symptoms?

Intake of coffee, tea, or soda is associated with an increased risk of gastroesophageal reflux (GER) symptoms, researchers report in the September issue of Clinical Gastroenterology and Hepatology. In contrast, consumption of water, juice, or milk is not associated with GER symptoms. Drinking water instead of coffee, tea, or soda reduces

Read more
  • What do Endoscopies Find in Patients With COVID-19?

What do Endoscopies Find in Patients With COVID-19?

Endoscopic examinations reveal abnormalities in a high proportion of COVID-19 cases, researchers report in Clinical Gastroenterology and Hepatology. Peptic ulcers and esophagitis were detected in most upper GI endoscopies, and colitis, ranging from mild to more severe ulcerative lesions, was the most common finding during colonoscopy. No endoscopists became infected

Read more
  • Summer Edition of the AGA Clinician’s Companion

Summer Edition of the AGA Clinician’s Companion

The summer edition of the AGA Clinician’s Companion—the new go-to resource for busy clinicians who can’t afford to spend hours sifting through research to find clinical value—is out! This latest edition of the AGA Clinician’s Companion, published online quarterly, summarizes research findings most relevant to clinicians on the risk of

Read more
  • Is Moderate Alcohol Use a Risk Factor for Nonalcoholic Liver Disease?

Is Moderate Alcohol Use a Risk Factor for Nonalcoholic Liver Disease?

Researchers report an association between alcohol use and liver fat—even after heavy users of alcohol were excluded from the analysis. Finding from the study, published in Clinical Gastroenterology and Hepatology, indicate that alcohol use is a risk factor for nonalcoholic fatty liver disease (NAFLD). Many individuals presumed to have NAFLD

Read more
Review: Cannabis and Its Derivatives in Gastrointestinal and Hepatic Disease

Review: Cannabis and Its Derivatives in Gastrointestinal and Hepatic Disease

Cannabis and its derivatives can have beneficial but also detrimental effects on gastrointestinal and hepatic function, via the endocannabinoid system (ECS). These are discussed in a review article in the July issue of Gastroenterology. Cannabis and its derivatives affect many gastrointestinal processes via the ECS and has reported anti-inflammatory, anti-nociceptive,

Read more

Addition of Nucleic Acid Polymers Improves Outcomes of Patients With HBV Infection

Addition of nucleic acid polymers (NAPs), which inhibit assembly and secretion of hepatitis B virus (HBV) subviral particles, to tenofovir disoproxil fumarate (TDF) and pegIFN therapy significantly increased rates of HBsAg loss and seroconversion, and functional cure, after therapy, researchers report in Gastroenterology. Chronic HBV infection causes progressive liver fibrosis,

Read more
  • Diarrhea and Other Gastroenterologic Effects of COVID-19

Diarrhea and Other Gastroenterologic Effects of COVID-19

Diarrhea is a frequent symptom in patients infected with SARS-CoV-2, researchers report in articles published in Clinical Gastroenterology and Hepatology. Researchers propose suspecting COVID-19 in any patient with diarrhea, even in the absence of respiratory symptoms, and taking appropriate precautions and approaching endoscopy as a procedure with high risk of

Read more

Nutritional Risks in Adolescents After Bariatric Surgery

Adolescents undergoing vertical sleeve gastrectomy (VSG) have fewer nutritional deficiencies than Roux-en-Y bypass (RYGB) at 5 years after the procedure, but both can produce deficiencies in iron and B12, researchers report in Clinical Gastroenterology and Hepatology. Ongoing nutrient monitoring and supplementation are recommended for all patients who receive bariatric surgery. 

Read more

Corticosteroids, but not TNF Antagonists, Associate With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases

Increasing age, comorbidities, and use of corticosteroids and other anti-inflammatory agents correlated with severe COVID-19 in patients with inflammatory bowel diseases (IBD), whereas treatment with tumor necrosis factor (TNF) antagonists did not, researchers report in Gastroenterology. Corticosteroids, immunomodulators (thiopurines, methotrexate), and biologic agents (TNF antagonists such as infliximab) are commonly

Read more

Is Antibiotic Prophylaxis Necessary During EUS-FNA of Pancreatic Cystic Lesions?

Risk of infection is low in patients undergoing endoscopic ultrasound with fine-needle aspiration (EUS-FNA) of pancreatic cysts, researchers report from a randomized controlled trial published in Gastroenterology. The incidence of infections did not differ significantly with vs without ciprofloxacin prophylaxis. The risk of pancreatic cyst infection after EUS-FNA is not

Read more

Increased Hospitalization and Mortality in Patients With COVID-19 and Pre-existing Liver Disease

More than half of patients with COVID-19 have markers of liver injury, researchers report in Gastroenterology. However, patients with pre-existing liver disease, and even more so those with cirrhosis, have increased risks for hospitalizations and death, the study found. Shailendra Singh and Ahmad Khan studied the effects pre-existing liver disease

Read more
  • AGA Clinical Practice Update: Pause IBD Meds For Patients With COVID-19

AGA Clinical Practice Update: Pause IBD Meds For Patients With COVID-19

Patients with inflammatory bowel diseases (IBD) with COVID-19 should delay biological therapies, restarting them once symptoms are gone, says a clinical practice update from the American Gastroenterological Association (AGA). The practice update, written by David T Rubin et al, says that patients with IBD who test positive for SARS-CoV-2 but

Read more